Competitive intelligence
Side-by-side comparison
Up to six companies on the same rows. Empty cells say what is missing rather than hiding it.
3 of 6 columns
Comparison
| Attribute | Moleculin Biotech, Inc.23.7remove | Veradermics, Inc24.0remove | Aptevo Therapeutics Inc.21.6remove |
|---|---|---|---|
| Signal scores | |||
| Radar composite | 23.7 | 24.0 | 21.6 |
| IPO signal score | 47.5 | 48.1 | 43.1 |
| Tokenization signal score | 0.0 | 0.0 | 0.0 |
| On-chain readiness | 0.0 | 0.0 | 0.0 |
| Momentum | ACCELERATING+22.3 | ACCELERATING+18.9 | ACCELERATING+26.1 |
| Company | |||
| Stage | public | public | public |
| Sector | not on record | not on record | not on record |
| Headquarters | HOUSTON | NEW HAVEN | SEATTLE |
| Founded | not on record | not on record | not on record |
| Employees | not on record | not on record | not on record |
| Capital | |||
| Latest valuation | not on record | not on record | not on record |
| Total funding | $6M | $45M | $3M |
| Latest round | Series E $6M | Private Placement $22M | Private Placement $3M |
| Investors on record | 0 | 0 | 0 |
| Evidence | |||
| Institutional relationships | 0 | 0 | 0 |
| Active signals | 50 | 19 | 63 |
| Confidence | 77% | 80% | 80% |
IPO Radar is a research and intelligence tool. Scores are signal scores derived from public evidence — they are not calibrated probabilities and not investment advice. FACT, INFERENCE and PREDICTION are kept separate, and every event links to its source.